Videos

Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.

Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.

The expert panel discusses trials underway in the adjuvant setting and the role of adjuvant therapy in patients with RCC.

Bradley McGregor, MD, reviews data from the Keynote-564 study on the use of immunotherapy in the adjuvant setting.

The expert panel discusses the role of multidisciplinary teams in treatment of patients with RCC.

Bradley McGregor, MD, reviews the case of a 62-year-old man with mRCC and the use of adjuvant therapy for RCC.

Dr Eric Jonasch and the panel discuss TIVO-3 trial data and use of tivozanib and HIF3α inhibitors in mRCC.

RCC experts discuss dose modifications and management of adverse events in patients with favorable-risk mRCC.

Eric Jonasch, MD, and the panel discuss NCCN Guidelines’ preferred second-line treatment options in mRCC.

The expert panel and Dr Eric Jonasch discuss data on first-line immunochemotherapy combinations for favorable-risk mRCC.

Eric Jonasch, MD, discusses a 62-year-old man with favorable-risk metastatic RCC and goals and treatment options for such a patient.

Shaji Kumar, MD, discusses how risk assessments and new drug combinations could influence treatment of patients with newly diagnosed multiple myeloma.

Arndt Vogel, MD, discusses the goals of the IMMUTACE study investigating the efficacy of transarterial chemoembolization with nivolumab in patients with intermediate-stage hepatocellular carcinoma.

Renal cell carcinoma panel discusses factors impacting first-line treatment selection and patient monitoring and adverse-event management in patients with intermediate- and poor-risk mRCC.

Tom Hutson, DO, PharmD, discusses efficacy and data from CheckMate 9ER, a phase 3 study, and considerations in selecting this regimen.

The expert panel discusses practical considerations when choosing first-line treatment in mRCC in light of CLEAR trial data.

Tom Hutson, DO, PharmD, reviews data from phase 3 CLEAR trial that evaluates efficacy and safety of frontline lenvatinib and pembrolizumab or everolimus or sunitinib.

Renal cell carcinoma experts discuss key efficacy data for first-line immunotherapy combinations in intermediate- and poor-risk patients with mRCC.

The expert panel discusses systemic therapy options recommended in NCCN Guidelines for patient with intermediate- and poor-risk mRCC.

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.

Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.

Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.

Mary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.

Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.

Dr Mary Mulcahy, a key opinion leader, describes the efficacy and safety outcomes of the EPOCH clinical trial.

The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.

Dr Mary Mulcahy explains the rationale and study design of the phase III EPOCH clinical trial.

Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.